Premium
Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy
Author(s) -
Hamel Johanna,
Lee Phil,
Glenn Melanie D.,
Burka Tekalign,
Choi InYoung,
Friedman Seth D.,
Shaw Dennis W. W.,
McCalley Ayla,
Herbelin Laura,
Dimachkie Mazen M.,
Lemmers Richard,
Maarel Silvère M.,
Barohn Richard J.,
Tawil Rabi,
Statland Jeffrey M.
Publication year - 2020
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.26792
Subject(s) - facioscapulohumeral muscular dystrophy , electrical impedance myography , magnetic resonance imaging , medicine , muscular dystrophy , tibialis anterior muscle , biomarker , intramuscular fat , dysferlin , reactance , skeletal muscle , bioelectrical impedance analysis , cardiology , physical medicine and rehabilitation , radiology , body mass index , chemistry , biochemistry , vasodilation , physics , quantum mechanics , voltage
Electrical impedance myography (EIM) has been proposed as a noninvasive biomarker of muscle composition in facioscapulohumeral muscular dystrophy (FSHD). Here we determine the associations of EIM variables with muscle structure measured by MRI. Methods We evaluated 20 patients with FSHD at two centers, comparing EIM measurements (resistance, reactance, and phase at 50, 100, and 211 kH Z) recorded from bilateral vastus lateralis, tibialis anterior, and medial gastrocnemius muscles to MRI skin and subcutaneous fat thickness, MRI T1‐based muscle severity score (T1 muscle score), and MRI quantitative intramuscular Dixon fat fraction (FF). Results While reactance and phase both correlated with FF and T1 muscle score, 50 kHz reactance was most sensitive to muscle structure alterations measured by both T1 score (ρ = −0.71, P < .001) and FF (ρ = −0.74, P < .001). Discussion This study establishes the correlation of EIM with structural MRI features in FSHD and supports further evaluation of EIM as a potential biomarker in FSHD clinical trials.